PMID- 33760412
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 0017-7768 (Print)
IS  - 0017-7768 (Linking)
VI  - 160
IP  - 2
DP  - 2021 Feb
TI  - [THE PRODROME OF PSYCHOTIC DISORDERS].
PG  - 104-109
AB  - Psychotic disorders are associated with a severe functional decline and a 
      significant impact on the quality of life. These disorders usually develop 
      gradually, lasting days to months-years. The early phase of psychotic disorders 
      is termed "pre-psychotic" or "prodromal". It is estimated that 30% of the 
      individuals presenting with prodromal symptoms will develop psychosis in three 
      years. This high-risk state is also known as "clinical high risk" (CHR), 
      "ultra-high risk" (UHR), and "at-risk mental state" (ARMS). The diagnostic 
      criteria of high-risk subjects include 3 groups: 1) genetic risk with a 
      functional decline; 2) brief limited intermittent psychotic symptoms group 
      (BLIPS); 3) subthreshold positive psychotic symptoms. In addition to the 
      psychosis risk, these subjects suffer from distress, functional deterioration and 
      psychiatric comorbidities that influence their quality of life. Therefore, many 
      efforts are invested in early identification of the high-risk for psychosis 
      subjects with the primary aim of using interventions to delay or prevent 
      conversion to psychosis. Studies in the field have highlighted specific factors 
      that predict the risk to develop psychosis and even developed predictive models. 
      Interventions including cognitive-behavioral therapy, integrative psychological 
      therapy and pharmacological therapy were found to be associated with postponing 
      the conversion to psychosis. According to current guidelines, cognitive 
      behavioral therapy is the first-choice intervention, and pharmacological 
      interventions should be reserved for patients with comorbidities in need of 
      stabilization of severe and progressive symptoms. Further prospective studies 
      will allow a better identification of high-risk patients and enable the 
      development of interventions for prevention and treatment of this population.
FAU - Lavan, Orly
AU  - Lavan O
AD  - Department of Psychological Medicine, Schneider Children's Medical Center of 
      Israel, Petah.
FAU - Apter, Alan
AU  - Apter A
AD  - Department of Psychological Medicine, Schneider Children's Medical Center of 
      Israel, Petah.
FAU - Benaroya-Milshtein, Noa
AU  - Benaroya-Milshtein N
AD  - Department of Psychological Medicine, Schneider Children's Medical Center of 
      Israel, Petah.
FAU - Fennig, Silvana
AU  - Fennig S
AD  - Department of Psychological Medicine, Schneider Children's Medical Center of 
      Israel, Petah.
LA  - heb
PT  - Journal Article
PT  - Review
PL  - Israel
TA  - Harefuah
JT  - Harefuah
JID - 0034351
SB  - IM
MH  - Humans
MH  - Prodromal Symptoms
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - *Psychotic Disorders/diagnosis/epidemiology/etiology
MH  - *Quality of Life
EDAT- 2021/03/25 06:00
MHDA- 2021/03/27 06:00
CRDT- 2021/03/24 13:16
PHST- 2021/03/24 13:16 [entrez]
PHST- 2021/03/25 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
PST - ppublish
SO  - Harefuah. 2021 Feb;160(2):104-109.